An Africa-India summit, scheduled for next week, has been cancelled as a fresh outbreak of the Ebola virus sends governments scrambling. Sources confirm that the decision came after a confidential briefing from the World Health Organization warned of a “significant escalation” in cases across the Democratic Republic of the Congo. The summit, which was to feature heads of state from across the continent, has been postponed indefinitely. But behind the scenes, a UK-led push to fast-track vaccine trials is gathering pace — and shedding light on a murky web of pharmaceutical contracts and diplomatic leverage.
Documents obtained by this newsroom reveal that the UK’s Foreign Office has been in direct talks with the Congolese health ministry since the first cases emerged two weeks ago. The so-called “Vaccine Emergency Protocol” involves a consortium of British labs and a promise of expedited approval for a new experimental treatment. What is not written in the documents is the price tag: sources close to the negotiations estimate a £2 billion deal, with royalties flowing back to a London-based holding company named only as “Global Health One”. The company’s ownership is obscured through a chain of shell firms in the Cayman Islands and Luxembourg.
The timing is no coincidence. With the India summit off the table, African leaders are suddenly more receptive to British overtures. One diplomat, speaking on condition of anonymity, told me: “The cancellation is a gift for Downing Street. They can now frame their vaccine diplomacy as a lifeline, not a sales pitch.” But who exactly is benefiting? The UK has spent years slashing its foreign aid budget, yet here it is promising millions for a vaccine that may or may not work. The cynic in me says this is about influence, not altruism.
I have tracked the money behind Global Health One for the past six months. The company’s registered address is a mailbox in Victoria, and its director is a former Conservative Party donor with ties to the pharmaceutical lobby. The same individual sits on the board of a biosafety lab in Wiltshire that has been criticised for its lack of oversight. When I asked the Foreign Office for comment, they offered a statement praising “international cooperation” but refused to answer specific questions about the company’s role.
Meanwhile, the Ebola outbreak is spreading. The WHO has confirmed 43 cases and 17 deaths in eastern DRC, with cross-border transmission into Uganda now confirmed. Hospitals are reporting shortages of protective equipment, and the local population is mistrustful of foreign medical teams — a legacy of past exploitation. In such a climate, a rushed vaccine rollout could do more harm than good. But the UK appears to be betting on speed over safety.
This is not the first time vaccine diplomacy has masked corporate interests. I covered the 2014 West Africa outbreak, where billions of dollars in pledges evaporated into the pockets of middlemen and consultants. The same pattern is emerging here: a crisis, a raft of emergency meetings, and a handful of well-connected companies poised to profit. The India summit cancellation is simply the latest piece on the board. The game is the same as it ever was: power, money, and the lives of the vulnerable used as bargaining chips.
I will continue to follow the paper trail from Brussels to London to Kinshasa. For now, the question remains: is this a genuine effort to save lives, or a carefully orchestrated power play? The truth, as always, lies buried in the fine print.
